| Similar Articles |
|---|
 |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.   |
AskMen.com
June 23, 2004
Joshua Levine |
Erection Drugs: Part II Thanks to modern medicine, a man can soon choose from a variety of new erection drugs. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
The Motley Fool
November 15, 2007
Brian Orelli |
Slowing the Cash Burn Bloody Nose Nastech plans to cut costs following Proctor& Gamble's drop of their osteoporosis drug. Investors, take note. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
Registered Rep.
June 1, 2004
Bob Hirschfeld |
The Virtue of Moderation With American obesity at epidemic proportions, diet products and weight-loss drugs are popular fare. However, many of the most promising obesity-control drugs await federal approval. |
The Motley Fool
July 14, 2006
Stephen D. Simpson |
FDA Bloodies Nastech's Nose An FDA rejection for a generic drug is a setback, but not a major one. Experienced biotech investors realize that ideas like Nastech are often binary outcomes -- it's either going to be a big winner or a total flop. |
The Motley Fool
May 16, 2007
Mike Havrilla |
Nastech Nose Potential The small biotech reports the achievement of positive results for carbetocin nasal spray for the treatment of autism symptoms along with the completion of a $41 million stock offering in January. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Bio-IT World
September 16, 2004
Paul King |
Growing Gains When it comes to information technology requirements, the biotech industry is unlike any other. A key enabler of efficient and effective growth is the adoption of IT strategies specific to each of four key stages. |
